In neurotropic flavivirus infections such as ZIKV—where immune responses can simultaneously control infection and contribute to pathology—therapeutic strategies must carefully balance CD8 T cell-mediated protection with the risk of collateral neural damage. This evidence concerns the gene CD8A and Flavivirus Infections.